1998
DOI: 10.1200/jco.1998.16.2.622
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: This intensive multimodality treatment is feasible and demonstrates high efficacy in prognostically unfavorable LAD-NSCLC subgroups with high R0 rates and improved long-term survival compared with historical controls

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

12
178
1
8

Year Published

2000
2000
2014
2014

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 309 publications
(199 citation statements)
references
References 33 publications
12
178
1
8
Order By: Relevance
“…Conversely, grade 3/4 esophagitis has been recorded in 8% to 53% of patients where radiation was delivered in a hyperfractionated accelerated fashion. [9][10][11]17,18 More importantly, no treatment-related deaths were observed in either arm in our trial during the induction and postoperative periods. Lobectomies may be safely performed following induction therapy, whereas pneumonectomy, especially on the right, may carry an unacceptable rate of perioperative mortality.…”
Section: Discussionmentioning
confidence: 65%
See 2 more Smart Citations
“…Conversely, grade 3/4 esophagitis has been recorded in 8% to 53% of patients where radiation was delivered in a hyperfractionated accelerated fashion. [9][10][11]17,18 More importantly, no treatment-related deaths were observed in either arm in our trial during the induction and postoperative periods. Lobectomies may be safely performed following induction therapy, whereas pneumonectomy, especially on the right, may carry an unacceptable rate of perioperative mortality.…”
Section: Discussionmentioning
confidence: 65%
“…A better response rate is typically achieved following a higher radiation dose (45 Gy) 14 or hyperfractionated accelerated irradiation. [9][10][11]15,17,18 An exploratory analysis showed that the OS of our patients with downstaging (72.1 months) was significantly better than that of patients without downstaging (31.2 months) in the CRS arm (P ¼ .008), although this survival benefit in patients with downstaging was not demonstrated in the CS arm (P ¼ .542). Although the in-field recurrence was significantly higher in the CS arm compared with the CRS arm, this did not translate to better PFS or OS in the CRS arm because there was no significant difference of distant and distant þ local recurrence between the 2 arms (CS vs CRS, 18/28; 64% vs 19/29; 65%).…”
Section: Discussionmentioning
confidence: 81%
See 1 more Smart Citation
“…described the brain as the most common site of recurrence (Burkes et al, 1992(Burkes et al, , 2005Albain et al, 1995;Darwish et al, 1995;Choi et al, 1997;Eberhardt et al, 1998;Mamon et al, 2005). Approximately, 40% of patients with stage IIIA NSCLC treated with preoperative chemotherapy and surgical resection have been reported to develop brain metastases (Andre et al, 2001;Mamon et al, 2005).…”
Section: Discussionmentioning
confidence: 99%
“…The results of the current and the aforementioned EORTC study (Van Zandwijk et al, 2000) suggest that GC regimen has achieved similar efficacy to cisplatin-based concurrent chemoradiotherapy as induction treatment in LAD-NSCLC patients. Incorporation of induction chemotherapy with concurrent chemoradiotherapy followed by radical surgery in the intensive tri-modal therapy has been successful in treating LAD-NSCLC patients (Eberhardt et al, 1998;Thomas et al, 1999). However, similar survival rates can be obtained with bi-modal treatment without surgery (Choy et al, 1998;Vokes et al, 1999).…”
Section: Discussionmentioning
confidence: 99%